Minimal late effects of stereotactic body radiation therapy for spine metastases years post treatment
Editorial Commentary

Minimal late effects of stereotactic body radiation therapy for spine metastases years post treatment

Samuel T. Chao1, Mihir Naik2

1Department of Radiation Oncology, Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 2Department of Radiation Oncology, Cleveland Clinic, Florida, Weston, FL, USA

Correspondence to: Samuel T. Chao, MD. Department of Radiation Oncology, College of Medicine, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Main Campus, Mail Code CA-50, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Email: chaos@ccf.org.

Provenance: This is an article commissioned by the Section Editor Dr. Hsin-Hua Nien (Attending physician, Department of Radiation Oncology, Cathay General Hospital, Taipei City).

Comment on: Ling DC, Flickinger JC, Burton SA, et al. Long-term outcomes after stereotactic radiosurgery for spine metastases: radiation doseresponse for late toxicity. Int J Radiat Oncol Biol Phys 2018;101:602-9.


Received: 09 August 2019; Accepted: 12 September 2019; Published: 20 September 2019.

doi: 10.21037/tro.2019.09.03


Introduction

Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) delivers high doses of radiation in 5 or fewer sessions or fractions. To do this safely, inherently it has to minimize dose to the surrounding normal tissue through very conformal and accurate delivery which have been developed and refined over the last decade. For spine metastases, there is increasing evidence that supports its efficacy, as well as safety. Ling et al. published in their manuscript, “Long-term outcomes after stereotactic radiosurgery for spine metastases: radiation dose-response for late toxicity”, their findings in regards to late toxicities and dosimetric factors that contribute to these toxicities in 43 patients who had follow-up of at least 5 years (1). This level of long-term follow-up makes this series unique.


Methods

The authors analyzed 562 patients with a minimum of 5 years of survival to look at the toxicities developed in patients after 5 to 10 years after SRS. All treatments were delivered in a single fraction to a dose ranging from 12 to 24 Gy. There was some variability with how the cord was contoured. In 62% of the patients, the entire spinal canal was contoured, but in the remaining 38%, the spinal cord was contoured. Toxicity was coded according to the CTCAE version 4.

The authors chose to calculate cumulative biological equivalent dose based on the linear quadratic model. While this is the most used model to compare dose, there is debate whether the linear quadratic model is accurate for SRS.

The authors looked at vertebral compression fractures (VCFs) as either de novo compression fracture or progression of pre-existing compression fracture.


Results

While excellent local control is seen at 1 year at 82.7%, it declines to 58% and 54% at 5 and 10 years respectively. This is consistent with data from other institutions. Nine patients out of 43 developed Grade 2 or more late toxicity in this series. Five patients had Grade 3 or more toxicity, 3 of which had painful sensory neuropathy, one had esophageal stricture, and one had urethral stricture requiring a stent. The patient with the urethral stricture also had a Grade 4 non-healing wound requiring hyperbaric oxygen. Both of the side effects are unusual, but need to be reported to fully understand potential issues that can develop post SRS depending on the treatment volume is contoured and the doses used. Three patients who developed sensory neuropathy post SRS also had prior external beam radiation therapy, which suggests cumulative dose does increase the risk for late effects. Cumulative BED3 >200 Gy appears to increase this risk, for both the sacral nerve roots and spinal cord.

VCFs occurred at a median of 10 months in 16.7% of the patients, consistent what is seen with other series. Unlike other studies however (2-5), they did not find factors that contributed to VCF, including age, gender, presence of pre-existing compression fracture, SRS dose, cumulative BED, and gross tumor volume.


Discussion

The strengths of this series are the number of patients with long term follow up as systemic therapies have improved survival in patients with metastatic disease. It is reassuring to see that there does not appear to be a dramatic increase in late effects many years out from SBRT. This knowledge is critical as SBRT is increasingly being utilized for benign tumors where long term late effects may be of even greater concern (6-8). Also of note, the modest dose used in spine SBRT comparative to lung SBRT may result in recurrence even after 5 to 10 years as has been reported in patients with lung malignancies (9). Ongoing follow up is necessary for this patients treated with spine SBRT as late recurrences can develop.

In regards to radiation myelopathy, one of the best data looking at the rate of complications and dose is provided from multi-institutional data comparing 9 patients with myelopathy against a large cohort from multiple academic institutions (10). This analysis used a logistic regression model yielding estimates of radiation myelopathy specific to SBRT. Thecal sac contours was used as a correlate for spinal cord contours and recommendations were given to limit the maximum point volume doses to what is summarized in Table 1 to reduce risk of radiation myelopathy to less than 5% (10). Other multi-institutional analysis have shown that re-irradiation with spine SBRT is safe and have reported no cases of radiation myelopathy, but have had limited patient follow up of a median 8.1 months (11).

Table 1
Table 1 Predicted Pmax (thecal sac point maximum) volume absolute doses in Gy for 1 to 5 SBRT that results in 1–5% probability of radiation myelopathy
Full table

VCF is another late complication seen with spine SRS. The risk of VCF range from 10% to up to 40%. This risk appears to be correlated to the dose per fraction. The rate of VCF is 10% at 1 year for fractional doses 19 Gy or less, but it is 39% for 24 Gy or more with the vast majority of VCFs occur within the first few months (2). This risk of fracture does need to be balanced with the potential for better control with higher doses. For those patients with a more limited life expectancy one may look to minimize risk of VCF which may lead to intervention at the end of life versus those patients with a longer life expectancy and excellent performance status who may be more willing to have an intervention for VCF and where disease control becomes more important. Potentially hypofractionated SRS can provide that higher ate of control without increasing the risk of radiation necrosis and studies have suggested low rates of VCF (12,13).


Acknowledgments

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


References

  1. Ling DC, Flickinger JC, Burton SA, et al. Long-Term Outcomes After Stereotactic Radiosurgery for Spine Metastases: Radiation Dose-Response for Late Toxicity. Int J Radiat Oncol Biol Phys 2018;101:602-9. [Crossref] [PubMed]
  2. Sahgal A, Atenafu EG, Chao S, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 2013;31:3426-31. [Crossref] [PubMed]
  3. Rose PS, Laufer I, Boland PJ, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 2009;27:5075-9. [Crossref] [PubMed]
  4. Boehling NS, Grosshans DR, Allen PK, et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 2012;16:379-86. [Crossref] [PubMed]
  5. Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys 2012;84:e343-9. [Crossref] [PubMed]
  6. Sachdev S, Dodd RL, Chang SD, et al. Stereotactic radiosurgery yields long-term control for benign intradural, extramedullary spinal tumors. Neurosurgery 2011;69:533-9; discussion 539. [Crossref] [PubMed]
  7. Gerszten PC, Chen S, Quader M, et al. Radiosurgery for benign tumors of the spine using the Synergy S with cone-beam computed tomography image guidance. J Neurosurg 2012;117 Suppl:197-202. [Crossref] [PubMed]
  8. Kalash R, Glaser SM, Flickinger JC, et al. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate? J Neurosurg Spine 2018;29:220-5. [Crossref] [PubMed]
  9. Matsuo Y, Shibuya K, Nagata Y, et al. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol 2012;7:453-6. [Crossref] [PubMed]
  10. Sahgal A, Weinberg V, Ma L, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013;85:341-7. [Crossref] [PubMed]
  11. Hashmi A, Guckenberger M, Kersh R, et al. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis. J Neurosurg Spine 2016;25:646-53. [Crossref] [PubMed]
  12. Redmond KJ, Sahgal A, Foote M, et al. Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the risk-benefit ratio. Future Oncol 2015;11:2405-15. [Crossref] [PubMed]
  13. Mehta N, Zavitsanos PJ, Moldovan K, et al. Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases. Adv Radiat Oncol 2018;3:245-51. [Crossref] [PubMed]
doi: 10.21037/tro.2019.09.03
Cite this article as: Chao ST, Naik M. Minimal late effects of stereotactic body radiation therapy for spine metastases years post treatment. Ther Radiol Oncol 2019;3:34.